The revision of the genomic structure of TSG101 implied that the majority of truncated transcripts that were observed in cancer and nonmalignant tissues are true alternative splice products that originate from exon skipping, rather than aberrant transcripts from cryptic splice sites as proposed earlier [2,9,10,11]. The gene discussed is TSG101; the disease is cancer.